BerandaLXRX • NASDAQ
add
Lexicon Pharmaceuticals Inc
$2,39
Setelah Jam Perdagangan Normal:(0,42%)+0,0100
$2,40
Tutup: 26 Jul, 18.18.34 GMT-4 · USD · NASDAQ · Pernyataan Penyangkalan
Tutup sebelumnya
$2,33
Rentang hari
$2,32 - $2,44
Rentang tahun
$0,92 - $3,73
Kapitalisasi pasar
863,85Â jt USD
Volume Rata-Rata
3,01Â jt
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Dalam berita
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
(USD) | Mar 2024info | Perubahan Y/Y |
---|---|---|
Pendapatan | 1,13Â jt | 4.608,33% |
Biaya operasional | 32,06Â jt | 67,50% |
Laba bersih | -48,40Â jt | -51,55% |
Margin laba bersih | -4,28Â rb | 96,78% |
Penghasilan per saham | -0,20 | -17,65% |
EBITDA | -45,19Â jt | -45,63% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
(USD) | Mar 2024info | Perubahan Y/Y |
---|---|---|
Investasi tunai jangka pdk | 355,60Â jt | 235,67% |
Total aset | 417,22Â jt | 156,41% |
Total liabilitas | 128,35Â jt | 71,89% |
Total ekuitas | 288,87 jt | — |
Saham yang beredar | 246,24 jt | — |
Harga terhadap reservasi | 1,99 | — |
Tingkat pengembalian aset | -35,05% | — |
Pengembalian modal | -38,14% | — |
Arus Kas
Perubahan bersih tunai
(USD) | Mar 2024info | Perubahan Y/Y |
---|---|---|
Laba bersih | -48,40Â jt | -51,55% |
Kas dari operasi | -55,13Â jt | -74,39% |
Tunai dari investasi | -110,22Â jt | -1.011,47% |
Tunai dari pembiayaan | 239,38Â jt | 29.151,33% |
Perubahan bersih tunai | 74,03Â jt | 463,89% |
Arus kas bebas | -37,14Â jt | -77,19% |
Tentang
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its patented mouse gene knockout technology and extensive in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.
The company's clinical drug candidates include sotagliflozin for the treatment of type 2 diabetes; LX1033 for the treatment of irritable bowel syndrome and other gastrointestinal disorders; telotristat ethyl for the treatment of the symptoms associated with carcinoid syndrome; and LX2931 for the treatment of autoimmune diseases, such as rheumatoid arthritis. Wikipedia
CEO
Didirikan
1995
Situs
Karyawan
285